Completed PHASE2 NCT00102310

YM443 in Subjects With Functional Dyspepsia

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Group, Dose Ranging Study of YM443 in Subjects With Functional Dyspepsia

Sponsor: Astellas Pharma Inc

Conditions Indigestion Nausea

Interventions YM443

Updated 7 times since 2017 Last updated: Jan 8, 2018 Started: Mar 10, 2004 Primary completion: Mar 11, 2006 Completion: Mar 11, 2006

A PHASE2 clinical study on Indigestion and Nausea, this trial is completed. The trial is conducted by Astellas Pharma Inc and has accumulated 7 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jan 2018 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Jan 2018 [monthly]

Completed PHASE2

First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Inc
Astellas Pharma US, Inc.

Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States , Asheville, United States , Atlanta, United States , Boston, United States , Bridgewater, United States , Brooklyn, United States , Charlottesville, United States , Chattanooga, United States , Chevy Chase, United States , Christiansburg, United States and 45 more locations